Velpanat
Utilized to address chronic hepatitis c and indicated to support viral clearance.
Strengths: 400/100mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Epclusa
- Therapeutic class
Antiviral
- Pharmacological class
HCV NS5B inhibitor; HCV NS5A inhibitor
- Contraindications
hypersensitivity to active substances
- Precautions and warnings
monitor hepatic function
- Minor side effects
headache; fatigue; nausea
- Moderate side effects
insomnia; rash
- Serious side effects
bradycardia — requires immediate medical attention
- Dosage forms
Tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Natco Pharma
- Onset Time
not applicable
- Duration
24 hours
- Storage instructions
Store below 30°C.
- Drug interactions
Amiodarone; Proton pump inhibitors; St. John's Wort
- Age restrictions
For adult use.
Patient summary
Utilized to address chronic hepatitis c and indicated to support viral clearance.
Mechanism of action
Velpanat combines a nucleotide polymerase inhibitor (sofosbuvir) and a replication complex inhibitor (velpatasvir) to block hepatitis C virus replication, effectively targeting the viral life cycle.
Pregnancy and breastfeeding
Pregnancy: Not recommended unless necessary provided by specialist. Breastfeeding: Consult specialist.
Velpanat
Utilized to address chronic hepatitis c and indicated to support viral clearance.
Editorial Notes
- Active ingredient(s): Sofosbuvir, Velpatasvir
- Listed indication(s): Chronic Hepatitis C
Available option
- 28 tablets - 400/100 mg1454-400-100-mg-17500